Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Evotec AG (DE:EVTA)
FRANKFURT:EVTA
Evotec AG (EVTA) Stock Price & Analysis
0 Followers
EVTA Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€4.52 - €12.00
Previous Close€4.52
Volume650.00
Average Volume (3M)291.00
Market Cap
€1.64B
Enterprise Value€1.81B
Total Cash (Recent Filing)€319.38M
Total Debt (Recent Filing)€506.67M
Price to Earnings (P/E)-9.1
Beta0.93
Next Earnings
May 22, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.50
Shares Outstanding353,905,306
10 Day Avg. Volume105
30 Day Avg. Volume291
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)2.59
Price to Sales (P/S)3.17
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€14.01Price Target Upside172.01% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Evotec AG News
PremiumCompany Announcements
T. Rowe Price Raises Stake in Evotec SE
Bulls Say, Bears Say
Bulls Say
Financial OutlookRevenue expectations exceed €1B in 2025 driven by the Action Plan 2025 and increasing royalty-based revenues.
Leadership ChangeNew CEO is seen as a top catalyst for the company.
Strategic PositioningEVO's differentiated end-to-end biologics manufacturing solution is well-positioned to take advantage of geopolitical dislocations.
Bears Say
Insider TransactionsDr. Lanthaler belatedly reported 3-years' worth of insider transactions of EVO shares, against the company policy.
Leadership StabilityCEO leaves for personal reasons after long tenure.
Operational RiskMajor disruption caused in 2023 by the mid-year cyberattack.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00%
Insiders
0.17% Mutual Funds
1.35% Other Institutional Investors
98.49% Public Companies and
Individual Investors
EVTA FAQ
What was Evotec AG’s price range in the past 12 months?
Evotec AG lowest stock price was €4.52 and its highest was €12.00 in the past 12 months.
What is Evotec AG’s market cap?
Currently, no data Available
When is Evotec AG’s upcoming earnings report date?
Evotec AG’s upcoming earnings report date is May 22, 2024 which is in 21 days.
How were Evotec AG’s earnings last quarter?
Currently, no data Available
Is Evotec AG overvalued?
According to Wall Street analysts Evotec AG’s price is currently Undervalued.
Does Evotec AG pay dividends?
Evotec AG does not currently pay dividends.
What is Evotec AG’s EPS estimate?
Evotec AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Evotec AG have?
Evotec AG has 355,084,200 shares outstanding.
What happened to Evotec AG’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Evotec AG?
Currently, no hedge funds are holding shares in DE:EVTA
---
Evotec AG Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€14.01 (172.01% Upside)
€14.01 (172.01% Upside)
Blogger Sentiment
Bullish
DE:EVTA Sentiment 100%
Sector Average 71%
Sector Average 71%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-43.72%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
3.19%
Trailing 12-Months
Company Description
Evotec AG
Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmes on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.
---
EVTA Company Deck
---
EVTA Earnings Call
Q4 2024
0:00 / 0:00
---
EVTA Stock 12 Months Forecast
Average Price Target
€14.01
▲(172.01% Upside)
Technical Analysis
Evotec AG
―
BioMarin Pharmaceutical
―
Arrowhead Pharmaceuticals
―
Neurocrine
―
Crispr Therapeutics AG
―
Best Analysts Covering EVTA
1 Year
1 Year Success Rate
2/6 ratings generated profit
1 Year Average Return
-23.57%
reiterated a buy rating 6 days ago
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -23.57% per trade.
---